Health Topics — Skin & Topical
Skin That Won't Calm Down
For the person with eczema, psoriasis, or chronic skin inflammation that conventional treatment has managed but not resolved — what the cannabinoid research has examined in skin tissue.
Chronic inflammatory skin conditions carry a particular kind of exhaustion. Not just the itch that wakes you at three in the morning. Not just the self-consciousness about what's visible. It's the relentlessness — the way eczema or psoriasis can feel managed one week and completely out of control the next, for reasons that don't always have obvious explanations. The searching for what triggered this flare. The frustration of treatments that work partially, or for a while, or not at all.
If you have been in that searching, the cannabinoid research in skin tissue is worth understanding — with its limits stated as clearly as its findings.
Skin has its own endocannabinoid system. CB1, CB2, and TRPV1 receptors are expressed across the epidermis and dermis — in keratinocytes (the primary skin cells), in sebaceous glands, in hair follicles, in skin-resident immune cells, and in the sensory nerve endings that carry itch and pain signals. The skin produces its own endocannabinoids locally. This is not a peripheral detail — it means the skin is a target tissue for cannabinoid research in its own right, not just a delivery route for systemic effects.
CB2 receptors in skin-resident immune cells regulate the inflammatory cytokines that drive conditions like psoriasis — the same immune signaling that triggers keratinocytes to proliferate abnormally fast, producing the characteristic scale and plaques. TRPV1 channels on sensory nerve endings in skin are directly involved in the itch signal that is the most disruptive symptom of eczema. When these receptors are dysregulated — or when the endocannabinoid system's local regulatory function is inadequate to the inflammatory demand — the skin loses its ability to settle.
What the research on CBG and CBD has found
CBG has been studied against abnormal keratinocyte proliferation — the cellular mechanism behind psoriatic scale — in laboratory culture. The Wilkinson study found that CBG inhibited keratinocyte cell division in a dose-dependent way, through mechanisms involving CB1, PPAR-γ, and possibly other pathways. The finding is specific and mechanistically grounded. It is also in vitro — isolated skin cells in a dish — and the distance from that to a treatment for psoriasis in a living person is real and significant.
CBD has interacted with TRPV1 channels in research — the sensory pathway most directly involved in the itch of eczema. CBD also reduces sebum production in sebaceous gland cell culture, which has implications for acne research. Small observational studies have examined topical CBD for atopic dermatitis and psoriasis with generally positive self-reported outcomes, but these are not controlled trials and cannot establish efficacy.
What neither CBG nor CBD has is a completed human randomized controlled trial for any inflammatory skin condition. The biological mechanisms are documented and genuinely relevant. The clinical evidence is not there yet. For a dermatologist or practitioner reviewing this area: the receptor biology is established, the in vitro findings are published, and the human trial gap is real.
On skin conditions and clinical care
Psoriasis and eczema are managed conditions with established clinical pathways — including prescription biologics, topical corticosteroids, phototherapy, and other approaches that have controlled trial evidence behind them. Nothing in this archive suggests that cannabinoid preparations replace or substitute for appropriate dermatological care.
The delivery question
Topical application is the most biologically logical route for skin conditions — the target tissue is the skin itself, and topical delivery avoids the first-pass metabolism that limits oral bioavailability. Research has confirmed that cannabinoids penetrate human skin and reach the viable epidermis and dermis. Whether they reach the concentrations demonstrated active in cell culture is a separate and open question.
Our massage oil preparation contains whole-plant CBD in a sunflower and jojoba carrier — both carrier oils known to support skin barrier function — alongside arnica and calendula, which we infuse ourselves. We don't claim it treats inflammatory skin conditions. We can say it is made from plants with documented skin-relevant biology, prepared with care, and formulated to support skin contact. What it does in any individual's skin is not something we have clinical trial data to predict.
The skin's endocannabinoid system is a real and documented system with genuine involvement in the inflammatory processes that drive conditions like eczema and psoriasis. The cannabinoid research in this area is mechanistically grounded and clinically unproven. What would change that picture — a well-designed human trial in a skin condition population — has not yet been done. We are watching the literature and will update this article when it does.
These statements have not been evaluated by the Food and Drug Administration. J.P. Hemp Company products are not intended to diagnose, treat, cure, or prevent any disease.